Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families
Authors: Haileyesus Getahun, Alberto Matteelli
Journal: Annals of Internal Medicine (2017)

Editorials21 November 2017Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and FamiliesCorrection(s) for this article:CorrectionsJan 2018Correction: Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and FamiliesFREEHaileyesus Getahun, MD and Alberto Matteelli, MDHaileyesus Getahun, MDWorld Health Organization Global TB Programme, Geneva, Switzerland (H.G.)Search for more papers by this author and Alberto Matteelli, MDUniversity of Brescia, Brescia, Italy (A.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2639 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This article has been corrected. The original version (PDF) is appended to this article as a Supplement.Tuberculosis (TB) is an ancient disease that remains a major public health crisis worldwide. Programmatic global approaches to diagnosis and treatment in largely self-presenting patients have cured nearly 70 million persons and saved more than 50 million lives in the past 2 decades (1). However, in 2016 an estimated 10.4 million persons developed the disease and 1.8 million died of it (1). Persons with latent Mycobacterium tuberculosis infection are an important source of new cases of active infection: 5% to 15% will develop ...References1. World Health Organization. Global Tuberculosis Report 2017. Geneva: WHO Pr; 2017. Google Scholar2. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127-35. [PMID: 26017823] doi:10.1056/NEJMra1405427 CrossrefMedlineGoogle Scholar3. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271-86. [PMID: 23244049] doi:10.1146/annurev-publhealth-031912-114431 CrossrefMedlineGoogle Scholar4. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1269-1278. [PMID: 27522233] doi:10.1016/S1473-3099(16)30216-X CrossrefMedlineGoogle Scholar5. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al; WHO's Global TB Programme. WHO's new End TB Strategy. Lancet. 2015;385:1799-801. [PMID: 25814376] doi:10.1016/S0140-6736(15)60570-0 CrossrefMedlineGoogle Scholar6. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531-7. [PMID: 24200264] doi:10.5588/ijtld.13.0423 CrossrefMedlineGoogle Scholar7. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection. A randomized trial. Ann Intern Med. 2017;167:689-97. doi:10.7326/M17-1150 LinkGoogle Scholar8. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015:CD003343. [PMID: 26022367] doi:10.1002/14651858.CD003343.pub4 CrossrefMedlineGoogle Scholar9. Sheridan SL, Harris RP, Woolf SH; Shared Decision-Making Workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention. A suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26:56-66. [PMID: 14700714] CrossrefMedlineGoogle Scholar10. Adams LV, Mahlalela N, Talbot EA, Pasipamire M, Ginindza S, Calnan M, et al. High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland. Int J Tuberc Lung Dis. 2017;21:1127-1132. [PMID: 28911356] doi:10.5588/ijtld.16.0946 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: World Health Organization Global TB Programme, Geneva, Switzerland (H.G.)University of Brescia, Brescia, Italy (A.M.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2639.Corresponding Author: Haileyesus Getahun, MD, Avenue Appia 11, 1211 Geneva, Switzerland; e-mail, [email protected]int.Current Author Addresses: Dr. Getahun: Avenue Appia 11, 1211 Geneva, Switzerland.Dr. Matteelli: Infectious Diseases Unit, Piazza Spedali Civili, 1 – 25125 Brescia, Italy.This article was published at Annals.org on 7 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families Metrics Cited byAdverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workersCorrection: Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families 21 November 2017Volume 167, Issue 10Page: 742-743KeywordsClinical trial reportingDecision makingGlobal healthInfectious diseasesIsoniazidPrevention, policy, and public healthRifapentineTreatment guidelinesTuberculosis ePublished: 7 November 2017 Issue Published: 21 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...